News

Lung evaluations via a CT scan might help predict the mortality risk in idiopathic pulmonary fibrosis (IPF) patients more accurately than the decline in forced vital capacity, a study shows. The study, “Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine…

A significant proportion of people with idiopathic pulmonary fibrosis (IPF) were found to have the sleep disorder restless legs syndrome (RLS), compared to a control group, according to new research. The data also showed that having RLS lowered sleep quality in IPF patients. The study, “Restless…

The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to healthcare, among other…

The Phase 2b GALACTIC-1 trial testing Galecto’s candidate GB0139 as an inhalation therapy for idiopathic pulmonary fibrosis (IPF) has recruited more than 150 patients to date, remaining on track despite the current COVID-19 pandemic, the company announced. The study (NCT03832946), underway across centers in the U.S.,…

Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. Royal Brisbane and Women’s Hospital‘s Human Research Ethics Committee has approved two sites — the Cairns…

GB0139, Galecto’s lead compound to treat various fibrotic diseases of the lungs, has shown strong anti-fibrotic activity in a mouse model of idiopathic pulmonary fibrosis (IPF) and in IPF patients in a completed Phase 2a trial. A randomized, double-blind and placebo controlled Phase 2b trial (NCT03832946)…

Loss of NEDD4-2 — a protein involved in the regulation of airway hydration and mucus clearance — leads to the onset and development of typical manifestations of idiopathic pulmonary fibrosis (IPF) in adult mice, a study has found. These findings, along with the establishment of a new animal…

Avalyn Pharma announced that it has raised $35.5 million in Series B funding to expand its pipeline and support clinical trials into AP01, its investigational inhalation treatment for idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction (CLAD). The company also reported recently completing enrollment for a clinical…